Compare Global X SuperDividend ETF (SDIV) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X SuperDividend ETF vs GeneDx Holdings Corp — how do they compare? Global X SuperDividend ETF trades at $24.87, while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Global X SuperDividend ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| SDIV | WGS | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $26.34 | $167.51 |
52-Week Low | $22.90 | $34.51 |
Market Cap | — | $1.80B |
Enterprise Value | — | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SDIV trades at $24.73, down 0.72% on the day, with a neutral technical signal and bearish moving averages. The ETF maintains a high yield strategy, evidenced by recent $0.18 dividends. Support is firm at $24, while resistance clusters around $25. News sentiment is mixed, highlighting its appeal for income but noting valuation concerns compared to growth-focused strategies.
Outlook hinges on income-seeking demand amid stable global small-cap value exposure. The primary opportunity is its 9%+ yield for diversification away from tech. Risks include sensitivity to interest rates and economic cycles affecting high-dividend stocks, with limited fundamental data increasing reliance on technical and sentiment factors.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
